Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well giving fludarabine phosphate, cyclophosphamide,
tacrolimus, mycophenolate mofetil and total-body irradiation together with a donor bone
marrow transplant works in treating patients with high-risk hematologic cancer. Giving low
doses of chemotherapy, such as fludarabine phosphate and cyclophosphamide, and total-body
irradiation before a donor bone marrow transplant helps stop the growth of cancer cells by
stopping them from dividing or killing them. Giving cyclophosphamide after transplant may
also stop the patient's immune system from rejecting the donor's bone marrow stem cells. The
donated stem cells may replace the patient's immune system cells and help destroy any
remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a
donor can also make an immune response against the body's normal cells. Giving tacrolimus and
mycophenolate mofetil after the transplant may stop this from happening